key: cord-0784281-1z40i2ag
authors: Alexander, Tobias; Greco, Raffaella
title: Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)
date: 2022-05-16
journal: Bone Marrow Transplant
DOI: 10.1038/s41409-022-01702-w
sha: 5f0c151f510773ad23815927cb1ac38711fad824
doc_id: 784281
cord_uid: 1z40i2ag

Autoimmune diseases (ADs) represent a heterogenous group of complex diseases with increasing incidence in Western countries and are a major cause of morbidity. Hematopoietic stem cell transplantation (HSCT) has evolved over the last 25 years as a specific treatment for patients with severe ADs, through eradication of the pathogenic immunologic memory and profound immune renewal. HSCT for ADs is recently facing a unique developmental phase across transplant centers. This review provides a comprehensive overview of the recent evidence and developments in the area, including fundamentals of preclinical research, clinical studies in neurologic, rheumatologic and gastroenterologic diseases, which represent major indications at present, along with evidence of HSCT for rarer indications. Moreover, we describe the interwoven challenges of delivering more advanced cellular therapies, exploiting mesenchymal stem cells, regulatory T cells and potentially CAR-T cell therapies, in patients affected by ADs. Overall, we discuss past and current indications, efficacy, associated risks and benefits, and future directions of HSCT and advanced cellular therapies in the treatment of severe/refractory ADs, integrating the available literature with European Society for Blood and Marrow Transplantation (EBMT) registry data.

Over the last 25 years, hematopoietic stem cell transplantation (HSCT) has been increasingly used to treat patients affected by severe and refractory autoimmune diseases (ADs) [1] . The majority of such patients have chronic diseases, which impact on quality-of-life and can shorten life expectancy but are rarely life-threatening in the short-term. Autologous and allogeneic HSCT are performed in this population after a careful balance of benefits and risks, and consideration of alternative treatment options [2, 3] , with the aim to ablate the aberrant immune system and reconstitute one more tolerant to selfantigens, inducing a complete and stable remission from disease activity [4] .

Recent evidence base, as developed across the international scientific research communities, explored HSCT as single one-off procedure to treat a variety of severe Ads [5] . Multiple sclerosis (MS) and systemic sclerosis (SSc) cover around 80% of transplants performed for ADs (Figs. 1, 2) , where HSCT has become an integral and standard-of-care part of treatment algorithms [6, 7] .

An analysis of trends across all ADs over the first 20 years of activity reflected the growth across indications, improvements in outcomes related to experience and center size, with some support for benefit of accreditation and economic factors [8] . A multidisciplinary approach is key in this field. The EBMT Autoimmune Diseases Working Party (ADWP) is central to bringing together HSCT and disease specialist communities. The AD section of the EBMT Registry is the largest database of its kind worldwide, reporting more than 3700 transplants.

In this review, we discuss past and current indications, efficacy, associated risks and benefits, and future directions of HSCT and advanced cellular therapies in the treatment of severe/refractory ADs, integrating the available literature with EBMT registry data. Moreover, we offer a thorough insight into the pathophysiology and management of ADs, and provide a general guidance on the entire transplant process, from the biological rationale and preclinical models to clinical results and recommendations.

Despite the clinical heterogeneity of ADs, many of them share common genetic and molecular patterns leading to a loss of tolerance and chronic immunologic self-reactivity [9] . On a cellular level, this is reflected by profound age-associated changes of B cells, such as decreased B-cell differentiation in the bone marrow [10] , redistribution of B-cell subsets in the periphery with a significant increase of proinflammatory (CD19 + CD27 − IgD − ) double-negative B cells [11] , and decreased expression of molecules involved in immunoglobulin class switching and somatic hypermutation, leading to decreased repertoire diversity and alterations of antibody responses [12] . Similarly, T cells undergo profound alterations during the aging process, ultimately resulting in immunosenescence [13] , most importantly associated with thymic involution with reduced T-cell receptor repertoire diversity [14, 15] . In contrast, antibody-secreting memory plasma cells, which are most recognizable for their longevity [16] , are stably maintained during aging [17] , as their survival is controlled by dedicated survival niches in the bone marrow [18] . Importantly, long-lived plasma cells not only provide protective humoral immunity, they also contribute to the chronicity of various ADs by the persistent secretion of pathogenic antibodies [19] , and thus, resemble novel therapeutic targets in autoimmunity [20] . The effect of HSCT on immunologic renewal has been the focus of many mechanistic studies. They collectively demonstrated that many of the age-or autoimmune-mediated immune disturbances may improve or even resolve [5] . For example, immune reconstitution studies indicated a predominant repopulation of CD27 − IgD + naïve B cells [21, 22] , a stable output of recent thymic emigrants [23, 24] , leading to a re-diversification of the receptor repertoire, and recurrence of both regulatory B and T cells in various Ads [25] [26] [27] [28] .

The initial concept of using HSCT as a means of controlling severe ADs was based on animal experiments and case reports showing long remission of 'coincidental' AD alongside standard hematological HSCT indications [29, 30] . Autologous HSCT is largely adopted to provide rapid and sustained hematopoietic recovery, supporting regimens of high-dose cytotoxic chemotherapy with lymphodepleting serotherapy (most commonly anti-thymocyte globulin, ATG). Nowadays, due to the less invasive collection methods and more rapid resolution of neutropenia and thrombocytopenia, peripheral blood stem cells (PBSCs) have largely replaced bone marrow as source, using cryopreservation techniques. After mobilization with granulocyte-colony stimulating factor (G-CSF) with or without cyclophosphamide (Cy), the graft is collected by leukapheresis and may be manipulated to enrich hematopoietic stem cells (CD34 selection) [31] and remove immune cells (ex vivo T cell depletion), potentially removing self-reactive lymphocytes [5] .

Different conditioning regimens may be administered before the reinfusion of the cells in patients affected by ADs. The overall intensity of the conditioning regimen [32] varies greatly according to disease indication, study protocol and center preference. The optimal intensity of the conditioning is still to be defined in ADs, due to wide clinical variability of patients and lack of direct comparative trials. The final intensity of the immunosuppression is affected by many factors (type of conditioning and inclusion/ dosage of serotherapy, mobilization chemotherapy, CD34 selection as graft manipulation, and prior treatments), leading to consider more 'treatment intensity' rather than just 'conditioning intensity' in the context of Ads [2, 5] . Reduced intensity [33] conditioning regimen significantly reduce the risk of treatment-related morbidity such as infections, infertility, organ damage, as well as treatment-related mortality (TRM). Indeed, there was chronological improvement in HSCT outcomes (i.e., progression-free survival, relapse/progression, and TRM), strictly connected to the transplant center experience, patient selection and progress with supportive care [8] .

HSCT exerts its therapeutic effect in ADs through various mechanisms, including the immunosuppressive conditioning regimen able to eradicate the autoreactive immunologic memory, and the regeneration and renewal of the immune system, leading to the re-induction of immune tolerance to rewire aberrant immune response toward self-antigens [26, 34] . Moreover, changes in the microbiome profile [35] , which have been linked to various ADs, merit further investigations in the context of immune recovery. The development of an immunological balance allows long-term disease remission [36] . 

Neurological ADs may affect the central and peripheral nervous systems, resulting in a variety of manifestations and symptoms. MS is currently the most frequent autoimmune disease for which HSCT has been used, accounting for 1875 patients reported in the EBMT registry (Fig. 1 ). Increasing evidence [5] support the use of autologous HSCT as highly effective therapeutic strategy for treatment-resistant inflammatory types of MS [33, [36] [37] [38] [39] [40] , for which it can be currently regarded as a standard of care [6] .

Remission of disease activity in patients with severe active MS undergoing autologous HSCT relies not only on the effect of highdose chemotherapy and intense lymphodepletion, but also on the renewal [34] of the immune compartment. Initially conceived as an extreme "rescue" therapy in MS patients with a poor prognosis who have failed all other therapies, delivery of HSCT subsequently changed [41] [42] [43] [44] [45] [46] [47] , including more patients in earlier inflammatory phases of the disease, with a gradual shift to a major predominance of relapsing remitting over progressive forms [8, 48] . This trend was also supported by the EBMT data [6] .

Many patients, especially in Europe, have been conditioned with "intermediate intensity" conditioning regimens, such as BEAM (BCNU 300 mg/m 2 on day −6, cytosine arabinoside, 200 mg/m 2 and etoposide 200 mg/m 2 day −5 to day −2, melphalan 140 mg/m 2 day −1) plus rabbit ATG in dose range of 5-7.5 mg/kg, showing satisfactory toxicity/efficacy equipoise, even in the longterm follow-up [36] . Recently, low intensity regimens involving administration of Cy and ATG have been adopted, showing prolonged time to disease progression as compared to approved disease-modifying therapy (DMT) [33] . New studies are required to better define the optimal conditioning and solve this current regimen selection controversy. Importantly, autologous HSCT seems to offer clear advantage in terms of NEDA (no evidence of disease activity), showing rates of 66-93% compared with alemtuzumab, natalizumab or ocrelizumab [6] .

In recent years, as clearly demonstrated by a marked decrease in TRM to 0.2%, better outcomes have been obtained owing to a growing experience in selecting the most appropriate patients to transplant, paralleled by advances in conditioning and support regimens [4, 8] . Despite the recent COVID-19 pandemic, the nonrelapse mortality (NRM, defined as death for whatever cause, without ever experiencing relapse) remains stable around 1% from 2015 through all the 2020, according to the recent EBMT registry data.

Moreover, HSCT may be considered as "clinical option" in carefully selected patients affected by rare treatment-resistant neurological Ads [6] . Autologous HSCT is effective also in refractory and aggressive neuromyelitis optica [49, 50] , chronic inflammatory demyelinating polyradiculoneuropathy [51] , as well as myasthenia gravis [52] , stiff-person syndrome disorder [53, 54] , and anti-GAD (glutamic acid decarboxylase)-mediated encephalitis [55] .

Although the areas of application of HSCT for rheumatic diseases have changed over the past 25 years, they still represent major indications with 1158 patients reported to the EBMT registry to date (Fig. 1) . Initially, HSCT has been applied for rheumatoid arthritis and juvenile idiopathic arthritis, where studies demonstrated mixed results with high rates of persistent or relapse of disease activity within 6 months of transplant requiring continued DMT [56, 57] , not justifying the further development of HSCT in these indications. Subsequently, HSCT has been utilized for systemic lupus erythematosus (SLE) with more than 300 patients being treated worldwide so far [5] . Data from large single-center experiences and multicenter trials indicate a disease-free survival of~50-66% at 5 years despite discontinuation of immunosuppressive and other targeted therapies [21, [58] [59] [60] [61] . Responding patients are usually free of clinical symptoms and may regain seronegativity for antinuclear antibodies, which is rarely seen under conventional therapies. Early use of HSCT also has the potential to protect against organ-failure and toxicity-related morbidity and improve quality-of-life [61] . The relapse rate is higher in patients receiving unmanipulated stem cell grafts and conditioning regimens without serotherapy [60] , potentially reflecting the reactivation of autoimmune responses initiated by residing long-lived memory plasma cells, which reasonably should be in the focus of future targeted approaches complementing Cy/ ATG-based regimens. Current evidence and expert consensus suggest HSCT in SLE as "clinical option", in patients with active disease despite chronic immunosuppression with or without Bcell-targeted therapies [62] [63] [64] . The main indication for HSCT has become rapidly progressive diffuse SSc, where even in the biologic's era, effective therapies capable of reversing tissue fibrosis and improving lung function are lacking [5] . Three randomized-controlled trials (RCTs) comparing autologous HSCT to intravenous Cy in SSc reported significant improvement in skin and broader disease-specific scores, with evidence for improvement of pulmonary function, skin fibrosis and quality-of-life [65] [66] [67] . A 5-year progression-free survival between 70 and 74% was reported in the multicenter European (ASTIS) and American (SCOT) trials and remained superior to monthly Cy in the control arm during the 10 years following HSCT in the ASTIS trial. The increased toxicity of HSCT in SSc compared to other indications was predominantly attributed to SSc-related cardiac dysfunction, especially related to pulmonary arterial hypertension, and Cy-induced cardiotoxicity. With improved screening procedures [68, 69] , as well as Cy-sparing conditioning regimens, TRM decreased from 10% in the ASTIS trial to 6% within a multicenter EBMT prospective study [7] , 3% in the SCOT trial [67] , and 2.4% in the CAST study [70] . Based on these data, SSc is recommended as 'standard indication' for autologous HSCT and endorsed by updated recommendations of the European League Against Rheumatism [71] . Rarer indications of HSCT for rheumatic diseases with positive results from retrospective EBMT studies include ANCA-associated vasculitis [72] , Takayasu arteritis [73] and Behcet's disease [74] .

The main area application of HSCT for gastroenterologic disease has been in inflammatory bowel disease [5] , particularly Crohn's Disease (CD) with 215 patients reported to the EBMT registry to date (Fig. 1) . In addition to single-arm series [75] [76] [77] [78] [79] , including a large EBMT retrospective study [80] , one RCT, the EBMT-sponsored ASTIC trial, has reported promising results. Although the ambiguous endpoint of the ASTIC study, i.e., no evidence of active disease on endoscopy or imaging with a CD activity index <150 for at least 3 months while off all CD medications, was not achieved, data supported improvement in clinical and endoscopic measures of activity and quality-of-life, with 50% of patients showing complete endoscopic mucosal healing [81] . Accordingly, CD is suggested as "clinical option" for HSCT and the EBMT and the European Crohn's and Colitis Organization (ECCO) provided a collaborative position paper to guide the current practice and forward development of HSCT in CD [82] . Future developments in the field include the utilization of low intensity regimens, currently investigated in the ASTIC-lite study [83] , and the use of umbilical cord blood (UCB) allogeneic HSCT, which already demonstrated a 5-year long clinical, endoscopic, and histologic disease-free and drug-free survival that occurred unexpectedly without donor engraftment or risk of graft-versus-host disease (GvHD) [84] .

Allogeneic HSCT is widely used to treat patients with malignant and nonmalignant hematological disorders [1] . This strategy may represent an attractive option for patients with refractory ADs, theoretically offering the advantage of complete eradication of autoreactive cells combined with the regeneration of a healthy immune system, tolerant to autoantigens [85] . In this context, the donor immune system plays a pivotal role in promoting a putative donor-versus-host alloreactivity [86, 87] .

During the last decade major changes have occurred in the field of allogeneic HSCT [88] [89] [90] , including the introduction of less aggressive conditioning regimens [91, 92] , improved patient selection, and better supportive care, with a substantial progress in reducing GvHD because of more accurate HLA-typing and better GvHD prevention drugs, opening this procedure also to nonmalignant disorders [93] [94] [95] [96] . Progressively the choice of donors and the sources of HSCs have enlarged, extending transplant indications to more patients [97] . Despite improved survival over time [98] , allogeneic HSCT use in AD has remained rare and largely restricted to immune cytopenia, pediatric practice, and carefully selected patients affected by monogenic autoinflammatory disorders presenting with "rheumatic" phenotype [96, [99] [100] [101] . A retrospective EBMT study reported better longterm outcomes in younger patients with more recent year of transplant [85] . However, its potential to provide long-term disease control in refractory ADs paves the way for extended clinical trials to better investigate its role mainly in younger patients [85] .

Alongside HSCT, innovative therapy approaches with immuneregulatory capacities such as mesenchymal stromal cells (MSC) and regulatory T cells (Tregs) have been developed over the last decades for treating severe Ads [5] . Published trials on advanced cellular therapies in this population are safe, while showing controversial beneficial effects, mainly due to a poor specificity of cell products related to a low number of true disease-relevant antigen-specific cells [102] [103] [104] [105] . The great variability among different trials and small numbers of patients warrants further studies in this setting.

Additionally, chimeric antigen receptor (CAR)-T cells [106] , one of the most promising therapy approaches for hematological malignancies, may be employed in the field of autoimmunity [107] , thanks to their ability of conferring new antigen-specificities and contemporary boosting cell activation. Early data on the successful treatment of a patient with refractory SLE with CD19targeted CAR-T cells has been recently reported [108] , showing encouraging results and paving the way to this new cell strategy.

Moreover, stem cells represent an important source for potential therapeutic interventions in regenerative medicine [5] . Among them, induced pluripotent stem cells (IPS) probably resemble the most promising future approach. IPS are generated from somatic cells that have been reprogrammed by the ectopic expression of defined embryonic transcription factors (typically: Oct3/4, Sox2, c-Myc, Klf4) called "Yamanaka factors" (OSKM) [109] . They are currently under investigation for the treatment of Parkinson's disease, macular degeneration and type I diabetes mellitus. In addition, neuronal stem cells (NSC) are increasingly evaluated as potential source for replacing damaged or lost neurons and glia [110] . Their therapeutic application already demonstrated promising results in the context of spinal cord injury in rodents [111] . Other areas of investigation include the exploitation of the inherent biologic advantages of UCB stem cells with high proliferative potential and good damage repair capacity [112] , and the biologic properties, therapeutic mechanisms and clinical efficacy of MSC or MSC-derived exosomes [113, 114] .

Two major transplant registries, the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), capture data from many ADs patients [5] .

In EBMT, quality in HSCT and cellular therapy is assured through the Joint Accreditation Committee of the International T. Alexander and R. Greco Society for Cellular Therapy and EBMT (JACIE) accreditation, which has been central to EBMT recommendations and may potentially affect the outcome of HSCT [8] . The EBMT Autoimmune Diseases Working Party (ADWP) is central to bringing together HSCT and disease specialist communities. The ADs section of the EBMT Registry is the largest database of its kind worldwide (Figs. 1, 2) . As of February 2022, a total of 3789 HSCT procedures (autologous in 93% of cases) for autoimmune indications have been reported in the EBMT registry. The CIBMTR Research Database captures outcomes of patients who receive an HSCT and follows patients longitudinally until death or lost to follow-up. The CIBMTR's study of HSCT for AID is overseen by the Nonmalignant Disease Working Committee. In the future, registry activity will continue to be essential for the further development of the field.

Current evidence support HSCT as a valid treatment option in the management of selected patients with ADs, with a clear risk/ benefit ratio as carefully evaluated by appropriately constituted multidisciplinary team (including transplant and disease specialists). HSCT can induce lasting remissions in patients with severe autoimmune disorders, underlying the value of these therapeutic approaches and the potential for immune reconstitution and immune resetting of T and B-cell repertoire. Center experience, accreditation, inter-specialty networking, and national socioeconomic factors are relevant for health service delivery of HSCT in ADs. New insights are coming also in the complexity and power of innovative cellular therapies. Future studies are warranted to further elucidate the mechanism of action of these cellular-based therapies, while shedding light on the underlying pathogenesis of ADs.

The datasets generated for this study are available on request to the corresponding author.

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

Hematopoietic stem cell transplantation for autoimmune disease

Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis

Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party

Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases

Inflamm-aging. An evolutionary perspective on immunosenescence

Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry

Aging effects on T-bet expression in human B cell subsets

Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children

Successful and maladaptive T cell aging

Diversity and clonal selection in the human T-cell repertoire

Immunosenescence: Implications for response to infection and vaccination in older people

Lifetime of plasma cells in the bone marrow

Humoral immunity due to long-lived plasma cells

Competence and competition: the challenge of becoming a long-lived plasma cell

Long-lived autoreactive plasma cells drive persistent autoimmune inflammation

Plasma cells as an innovative target in autoimmune disease with renal manifestations

Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system

Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients

Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients

Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients

Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus

Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients

T cell repertoire following autologous stem cell transplantation for multiple sclerosis

Extensive intrathecal T cell renewal following hematopoietic transplantation for multiple sclerosis

Haematopoietic stem cell transplantation in autoimmune diseases: from basic science to clinical practice

Hematopoietic stem cell therapy for autoimmune diseases-clinical experience and mechanisms

Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? Bone Marrow Transplant

Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?

Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial

Immune reconstitution following autologous hematopoietic stem cell transplantation for multiple sclerosis: a review on behalf of the EBMT Autoimmune Diseases Working Party (ADWP). Front Immunol

Intestinal microbiome in hematopoietic stem cell transplantation for autoimmune diseases: considerations and perspectives on behalf of autoimmune diseases working party (ADWP) of the EBMT

Longterm Outcomes After Autologous hematopoietic stem cell transplantation for multiple sclerosis

Longterm clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis

Autologous haematopoietic stem cell transplantation as a first-line diseasemodifying therapy in patients with 'aggressive' multiple sclerosis

Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT)

Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial

Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience

Autologous hematopoietic stem cell transplantation with reducedintensity conditioning in multiple sclerosis

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report

Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis

Autologous bone marrow transplantation for the treatment of multiple sclerosis

Autologous hematopoietic stem cell transplantation for multiple sclerosis-if confused or hesitant, remember: 'treat with standard immune suppressive drugs and if no inflammation, no response

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper

Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party

Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica

Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy

Myasthenia gravis treated with autologous hematopoietic stem cell transplantation

Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience

Autologous Hematopoietic Stem Cell Transplantation for Stiff-Person Spectrum Disorder: A Clinical Trial

Nonmyeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis

Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR

Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity

Autologous stem cell transplantation for systemic lupus erythematosus

Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus

Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry

Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome

Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe

Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus

Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation

Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial

Autologous Stem-Cell Transplantation for Severe Scleroderma

Cardiac assessment before stem cell transplantation for systemic sclerosis

Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners

Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days

Update of EULAR recommendations for the treatment of systemic sclerosis

Autologous haematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a retrospective survey of patients reported to European Society for Blood and Marrow Transplantation (EBMT) registry

Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in refractory Takayasu arteritis: a retrospective multicenter case-series from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Autologous Hematopoietic Stem Cell Transplantation for Behcet's Disease: A Retrospective Survey of Patients Treated in Europe, on Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation

Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease

Autologous stem cell transplantation in severe treatment-resistant Crohn's disease: long-term follow-up of UK patients treated on compassionate basis

Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease

Autologous haematopoietic stem cell transplantation for refractory Crohn's disease: efficacy in a single-centre cohort

Low toxicity and favorable clinical and quality of life impact after nonmyeloablative autologous hematopoietic stem cell transplant in Crohn's disease

Autologous haematopoietic stem cell transplantation for crohn's disease: a retrospective survey of long-term outcomes from the European Society for Blood and Marrow Transplantation

Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial

Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: a review on behalf of ECCO and EBMT

Autologous stem cell transplantation in refractory Crohn's disease -low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study

A pilot feasibility study of non-myeloablative allogeneic hematopoietic stem cell transplantation for refractory Crohn Disease

Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMT ADWP, IEWP, and PDWP working parties

Tolerance induction by bone marrow transplantation in a multiple sclerosis model

Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect

High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel

Post-transplant cyclophosphamide and sirolimus based graft-versus-host-disease prophylaxis in allogeneic stem cell transplant. Transplant Cell Ther

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, noninferiority, phase 3 trial

Treosulfan-based conditioning regimen prior to allogeneic stem cell transplantation: long-term results from a Phase 2 clinical trial

Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica

T-cell depleted HLA-haploidentical HSCT in a child with neuromyelitis optica

Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis

Haematopoietic stem cell transplantation in paediatric rheumatic disease

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT

Allogeneic hematopoietic SCT for patients with autoimmune diseases

Long-term outcomes of hematopoietic stem cell transplantation for severe treatmentresistant autoimmune cytopenia in children

Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens

Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience

Combining systemic and locally applied cellular therapies for the treatment of systemic sclerosis

Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

Chimeric antigen receptor based therapy as a potential approach in autoimmune diseases: how close are we to the treatment?

CD19-targeted CAR T cells in refractory systemic lupus erythematosus

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

Therapeutic plasticity of neural stem cells

Therapeutic potential of induced neural stem cells for spinal cord injury

A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential

Effects of mesenchymal stem cellderived exosomes on autoimmune diseases

The clinical trials of mesenchymal stromal cells therapy

The authors contribute this article on behalf of ADWP of the EBMT. The authors thank Manuela Badoglio and Myriam Labopin in the EBMT Paris Office for provision of data from the EBMT registry, EBMT centers for their contributions to the registry and those

active in the ADWP. The authors thank Prof. Burt, Prof. Farge, Prof. Ruiz, Prof. Saccardi, and Prof. Snowden for the effort in creating a huge international reference work in the context of ADs. The authors are profoundly grateful to Prof. Burt also for his clinical and research practice of HSCT in ADs, a field in which he has been one of the world leaders, and, indisputable, the principal pioneer in the field based upon his major contributions.

RG and TA led on concept, design, coordination and data review, provided expert and analytical feedback and were both involved in reviewing, writing and editing the paper. The two co-authors were involved in drafting the paper, revising it critically, and approval of the submitted and final versions.

RG discloses speaking honoraria from Biotest, Pfizer, Medac, and Magenta. TA declares speaking honoraria from Amgen, Roche, Pfizer, travel grants from Neovii, and study support from Amgen, Janssen-Cilag, and Miltenyi Biotec.

This review was led and supported by the EBMT-ADWP. The EBMT provided resources via the working party, data office, and registry. Other than EBMT support there is no funding body supporting these guidelines, commercial or otherwise.

Correspondence and requests for materials should be addressed to Tobias Alexander or Raffaella Greco.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons. org/licenses/by/4.0/.